Treatment of rare mutations in patients with lung cancer

Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya

Research output: Contribution to journalReview articlepeer-review


Lung cancer is a worldwide prevalent malignancy. This disease has a low survival rate due to diagnosis at a late stage challenged by the involvement of metastatic sites. Non-small-cell lung cancer (NSCLC) is presented in 85% of cases. The last decade has experienced substantial advancements in scientific research, leading to a novel targeted therapeutic approach. The newly developed pharmaceutical agents are aimed towards specific mutations, detected in individual patients inflicted by lung cancer. These drugs have longer and improved response rates compared to traditional chemotherapy. Recent studies were able to identify rare mutations found in pulmonary tumors. Among the gene alterations detected were mesenchymal epithelial transition factor (MET), human epidermal growth factor 2 (HER2), B-type Raf kinase (BRAF), c-ROS proto-oncogene (ROS1), rearranged during transfection (RET) and neurotrophic tyrosine kinase (NTRK). Ongoing clinical trials are gaining insight onto possible first and second lines of medical treatment options intended to enable progression-free survival to lung cancer patients.

Original languageEnglish
Article number534
Issue number5
StatePublished - May 2021
Externally publishedYes


  • Clinical trials
  • Gene alterations
  • Lung cancer
  • Mutations
  • Non-small cell lung cancer
  • Pharmaceutical agents
  • Progression-free survival
  • Response rate
  • Side effects
  • Targeted therapy


Dive into the research topics of 'Treatment of rare mutations in patients with lung cancer'. Together they form a unique fingerprint.

Cite this